|
|
|
|
|
Eli Lilly to Stop Producing Humulin®50/50 insulin
See This Week's Item #13
|
|
|
2nd DPP-4 inhibitor gets FDA Approval
Onglyza™ (saxagliptin) a new DPP-4 inhibitor similar to Januvia will give physicians another option in treating their patients with diabetes. See This Week's Item #1 (http://www.diabetesincontrol.com/index.php?option=com_content&view=article&id=8185&catid=1&Itemid=8).
|
|
|
New Insulin Patch gets FDA Approval
A new mini tubeless insulin infusion patch will go on sale in the U.S.. See this week’s new product information and check out This Week's Item #4.
|
|
|
New NIH Study Results Show Intensive Control Reduces Complications by More Than 50% - See This Week's Item #1 (http://www.diabetesincontrol.com/index.php?option=com_content view=article id=8155)
|
|
|
Medtronic Diabetes is voluntarily recalling Quick-set® infusion sets that have lot numbers starting with the number "8". These infusion sets are used with MiniMed Paradigm® Insulin Pumps. The action was taken because of a situation related to the tubing connector which may not allow the insulin pump to vent properly. If the vent does not work properly, this could potentially result in too much or too little insulin being delivered and may lead to serious injury or death. All patients who have been shipped "Lot 8" Quick-set infusion sets are being instructed to discontinue using them immediately. Patient letter (http://www.medtronicdiabetes.com/lot8/qs_lot8_patientletter.pdf) and Q A (http://www.medtronicdiabetes.com/lot8/qs_lot8_qanda.pdf) for your reference.
|
|
|
POSSIBLE LINK BETWEEN INSULIN GLARGINE AND CANCER QUESTIONED - MORE RESEARCH REQUIREDExperts stress patients should not stop using insulin and consult their doctor if concerned. See This Week’s Item 1 (index.php?option=com_content id=8041)Takeda’s Diabetes Drug Alogliptin Rejected by FDA Asia’s biggest drugmaker, Takeda, failed to gain U.S. regulatory approval to market its new diabetes drug alogliptin because of insufficient data. The U.S. Food and Drug Administration issued a so-called complete-response letter saying the company must provide more data on cardiovascular risks. More information in next week's issue.
|
|
|
Controlling blood sugars may not be enough to prevent the complications of diabetes. See this week’s Item 6 (/index.php?option=com_content view=article id=8009 catid=1 Itemid=8)
|
|
|
ADA confirms that the A1c test will be used for the diagnosis of diabetes. Fasting
blood sugar tests will no longer be necessary to diagnosis diabetes. The A1c test can
be done anytime without regard to meals.
ADA - International Expert Committee Recommends A1c Test to Diagnose Diabetes (index.php?option=com_content view=article id=6981:ada-international-expert-committee-recommends-a1c-test-to-diagnose-diabetes catid=53:diabetes-news Itemid=8)
|
|
|
The FDA has informed us that some stolen vials of the long-acting insulin Levemir made by Novo Nordisk Inc., are being sold in the U.S. market. They may not have been
stored and handled properly, and may be dangerous for patients to use. The agency is advising
patients who use Levemir insulin to check their vials of following lots: XZF0036, XZF0037, and
XZF0038. Contact the Novo Nordisk Customer Care Center at 1-800-727-6500 if you have one.
|
|
|
The American Clinical Board of Nutrition (ACBN) offers our readers the first NCCA recognized certificate in nutrition.
|
|
|
Disetronic Medical Systems Inc. and FDA have recalled some ACCU-CHEK Spirit insulin pumps.
Hydroxycut Weight Loss Nutritional Products Recalled:
|
|
|
Diabetes Drugs Must Now Clear Cardiovascular Hurdle, Says FDA.
|
|
|
Senator Edward Kennedy Honored With American Diabetes Association's Distinguished Service Achievement Award
|
|
|
More Information: Animas Insulin Pumps: Battery Caps
|
|
|
Phase 3 study confirms that liraglutide treatment leads to both glucose and weight reduction with a low risk of hypoglycaemic events
Novo Nordisk today announced clinical results from the fourth of five phase 3 studies with liraglutide
|
|
|
Change in Daylight Saving Time May Cause Medical Device
Errors for Pump Users
The change which started last Sat evening for
the beginning and end of daylight saving time (DST) may adversely affect
medical equipment that uses date and time information for diagnosis or treatment.
The new DST will begin 3 weeks earlier and end one week later this year. See
this week's Item #9
The 19th annual American Diabetes Alert(r) Day is Tuesday
March 27, 2007
Check out this weeks Tools for Your Practice and Print out the Take the Test
form!
Dr. Richard K. Bernstein's 2007 Edition of Diabetes
Solution is available now!
Check it out at: http://www.diabetes911.net (http://www.diabetes911.net/)
|
|
|
St. Petersburg Times, Dec 7, 2003
TheraSense Files Premarket Approval Application for Freestyle Navigator(TM) Continuous Glucose Monitor-- The PMA filing follows recently presented clinical data on Navigator that included results of home-use trials involving 102 subjects at 7 clinical sites. FreeStyle Navigator is a continuous glucose monitor designed to replace traditional in vitro glucose testing by providing users with real time glucose data, hypo- and hyperglycemic alarms and trend analysis. Navigator is designed to measure glucose levels in the patient's interstitial fluid every sixty seconds and transmit the results to a wireless pager-sized receiver that may be worn on a belt or carried in a pocket or purse. More Information as it becomes available.
|
|
|
Abbott Diabetes Care, a division of Abbott Laboratories , said late Friday that it has voluntarily initiated a correction and notification to users of its blood glucose meters in the U.S. Abbott's blood glucose meters are designed to allow patients to display one of two standard units of measure: milligrams per deciliter, the U.S. standard, or millimoles per liter, a standard commonly used in other countries.
|
|
|
Novartis Nutrition Corporation Issues Nationwide Recall of One Lot of Its Diabetisource(R) AC Product - They are recalling 2,712 bottles of an enteral feeding formula which was incorrectly labeled as Diabetisource(R) AC 1.5 Liter bottles lot 2135L. More Information
|
|
|
Why bother to be interested in Lilly’s re-introduction of Humalog 50/50? I look forward to this as it comes closer to mimicking the bodies own insulin release, and for my patients it reduces the chance of nocturnal hypoglycemia. Learn more about how this formulation makes a difference by checking out our newsflash.
|
Entries (RSS News)
